January 06, 2026 a 01:01 pm
DGX: Analysts Ratings - Quest Diagnostics Incorporated
Quest Diagnostics Incorporated (DGX), a prominent player in the diagnostic testing industry, has exhibited stable performance amidst an array of market challenges. With a strong focus on innovation, the company continues to deliver comprehensive diagnostic information services. This analysis delves into the recent analyst ratings and evaluates the sentiment and trends shaping the stock's outlook.
Historical Stock Grades
The latest analyst ratings for Quest Diagnostics Incorporated as of January 2026 are noteworthy. The data shows a significant inclination towards 'Hold' recommendations, indicating a conservative market sentiment at present. Here are the detailed numbers for DGX:
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 7 | |
| Hold | 10 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, Quest Diagnostics has experienced a shift in analyst sentiment. The inclination towards 'Hold' ratings has markedly increased while maintaining a steady number of 'Buy' recommendations. Notably, the 'Strong Buy' category has seen a decline over the past year.
- The total analyst coverage has been consistent, with minor variations in recommendation distribution.
- A notable trend is the decline in 'Strong Buy' ratings from 5 in September 2024 to 1 in January 2026.
- 'Hold' recommendations have consistently been the majority, reflecting a cautious sentiment.
Percentage Trends
An analysis of the percentage distribution of ratings reveals insightful changes. The shift from 'Strong Buy' towards 'Hold' indicates market caution, particularly in a challenging economic environment.
- In January 2026, nearly 59% of analyst recommendations are 'Hold', up from 43% in October 2024.
- 'Strong Buy' recommendations dropped from 18% to approximately 5% over the past year.
- This trend suggests a growing sense of caution among analysts, possibly influenced by macroeconomic factors.
- The stock's sentiment reflects an increased preference for stability over aggressive growth expectations.
Latest Analyst Recommendations
Recent analyst activities have primarily focused on maintaining existing ratings, indicative of steady confidence in DGX's current operating stance.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-27 | Neutral | Neutral | Piper Sandler |
| 2025-10-22 | Hold | Hold | Truist Securities |
| 2025-10-22 | Equal Weight | Equal Weight | Barclays |
| 2025-10-21 | Outperform | Outperform | Leerink Partners |
| 2025-10-21 | Buy | Buy | Jefferies |
Analyst Recommendations with Change of Opinion
There have been a few shifts in recommendations throughout the past year, most notably involving downgrades and upgrades which signal strategic reassessments by analysts.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-25 | Neutral | Outperform | Baird |
| 2025-03-04 | Neutral | Buy | Citigroup |
| 2025-01-06 | Outperform | Market Perform | Leerink Partners |
| 2024-12-17 | Overweight | Equal Weight | Morgan Stanley |
| 2024-10-23 | Outperform | Neutral | Baird |
Interpretation
Current market sentiment towards Quest Diagnostics appears conservative, underscored by a significant proportion of 'Hold' ratings. While the downgrades highlight a cautious approach, the maintenance of 'Buy' and 'Outperform' ratings signify a balanced outlook with potential for stability. This implies a market in hold mode, perhaps awaiting more robust data or market catalysts. The consistency in analyst recommendations suggests a solid but cautious confidence in the company’s strategic direction.
Conclusion
Quest Diagnostics Incorporated remains a stable entity within the healthcare diagnostics sector. Its focus on innovation and service delivery affords it durability despite shifting market sentiments. The observable trends indicate cautious optimism, as evidenced by a substantial number of 'Hold' ratings. Risks include market saturation and economic downturns, while opportunities are geared towards technological advances and expanding healthcare needs. Overall, the stock remains attractive for those seeking steady performance with restrained growth expectations in the short to medium term.